• Waters Corporation recently launched the omniDAWN Multi-Angle Light Scattering Photometer, an extended-range MALS detector for UHPLC and UPLC workflows, and supported FDA-cleared at-home use of the Onclarity HPV Self-Collection Kit in collaboration with BD, expanding its role in advanced analytical and diagnostic solutions.
• By combining higher-throughput, lower-consumption biopharma analytics with at-home HPV screening infrastructure, Waters is reinforcing its position at the intersection of laboratory instrumentation and accessible diagnostics.
• Against this backdrop, we will examine how omniDAWN’s expanded UHPLC/UPLC sizing capabilities may influence Waters’ investment narrative and growth drivers.

Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Waters Investment Narrative Recap

To own Waters, you need to believe that its core analytical instruments and expanding diagnostics footprint can keep justifying a premium valuation, even as integration and funding risks persist. The omniDAWN launch and FDA-cleared Onclarity HPV self-collection kit both support Waters’ push into higher-value workflows, but they do not fundamentally change the near-term execution risk around the BD Biosciences and Diagnostic Solutions integration or the pressure from softer academic and pharma discovery budgets.

Among the recent announcements, the restructuring into four divisions, including Waters Biosciences and Waters Advanced Diagnostics, feels most relevant here, because it frames how omniDAWN and the HPV self-collection collaboration may plug into a more focused organization. If the new division structure helps Waters better coordinate complex launches like omniDAWN and manage higher-throughput diagnostic partnerships, it could support the existing catalyst of recurring revenue growth while potentially sharpening how the company addresses its integration and competitive risks.

Yet beneath these product wins, investors should still be aware that...

Waters' narrative projects $7.5 billion revenue and $1.4 billion earnings by 2029. This requires 33.5% yearly revenue growth and a $757.4 million earnings increase from $642.6 million today.

Uncover how Waters' forecasts yield a $393.14 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected Waters to reach about US$3.7 billion in revenue and US$935.6 million in earnings by 2028, so if you see omniDAWN and at-home HPV testing as early answers to the risk of lagging digital and automated platforms, you may view this news as strengthening that more ambitious narrative rather than the more cautious consensus.

Explore 2 other fair value estimates on Waters - why the stock might be worth just $393.14!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Waters research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Waters research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Waters' overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.